Physician profile
Robert M Aaronson
NPI 1346247657
$2,855.57
in general payments reported to CMS, 2019-2025
31 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $178 · 2021: $338 · 2022: $410 · 2023: $626 · 2024: $459 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $340.15 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.33 | 2021-2025 | Ofev, Stiolto Respimat |
| Amgen INC. | $196.92 | 2021-2025 | Tezspire, Tavneos |
| Astrazeneca Pharmaceuticals LP | $192.76 | 2019-2024 | Fasenra |
| Insmed, INC. | $186.95 | 2019-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $182.09 | 2019-2025 | |
| Harmony Biosciences LLC | $181.02 | 2023-2024 | Wakix |
| Electromed, INC. | $173.82 | 2019-2025 | Smartvest |
| Edwards Lifesciences Corporation | $146.80 | 2024 | Pascal |
| Abbott Laboratories | $132.93 | 2022 | |
| Abiomed | $114.15 | 2020 | |
| Amarin Pharma, INC. | $82.67 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $77.62 | 2022-2023 | Opsumit, Uptravi |
| Genentech USA, INC. | $73.64 | 2019-2024 | Xolair |
| Mylan Specialty L.P. | $58.01 | 2021-2024 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $53.22 | 2023-2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $45.27 | 2024-2025 | Dupixent |
| Tactile Systems Technology INC | $44.44 | 2024 | Flexitouch Plus, Entre Plus |
| Novartis Pharmaceuticals Corporation | $43.22 | 2019-2023 | |
| Baxter Healthcare | $37.95 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $33.74 | 2025 | Ohtuvayre |
| Vapotherm INC | $33.36 | 2021 | |
| Merck Sharp & Dohme LLC | $25.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.74 | 2019-2020 | |
| Grifols USA, LLC | $23.63 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $22.82 | 2025 | Inspire |
| Viatris Specialty LLC | $22.40 | 2025 | Yupelri |
| Genzyme Corporation | $20.23 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $17.10 | 2025 | Arctic Sun 5000 |
| Pulmonx Corporation | $15.49 | 2020 | |
| Apria Healthcare LLC | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aaronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.